Suppr超能文献

生物多样性勘探利益分享中的法律问题。

Legal issues in sharing the benefits of biodiversity prospecting.

作者信息

Mays T D, Mazan K D

机构信息

Office of Technology Development, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

出版信息

J Ethnopharmacol. 1996 Apr;51(1-3):93-102; discussion 102-9. doi: 10.1016/0378-8741(95)01352-0.

Abstract

The National Cancer Institute (NCI) is the US Government's principal agency for research on the prevention, diagnosis and treatment of cancer. A critical component of the Institute's mission is the identification and development of new and promising treatments for cancer and AIDS. For many years these efforts have included a program to investigate natural products for potential new therapeutic agents. In 1986, with the advent of new screening techniques, the National Cancer Institute stepped up its exploration of natural products and began world-wide collections of plants in tropical and subtropical regions. In recognition of the principles of the Biodiversity Treaty, NCI appreciates that continued access to the natural products of these countries depends on the Institute's ability to recognize the contributions of these source countries and their indigenous peoples, and to provide them adequate incentives to conserve their natural resources for the purposes of drug discovery. Accomplishing this goal presented several legal issues for the National Cancer Institute. As an agency of the US government, the NCI has an adjunct statutory mission to facilitate the transfer of technology developed through the Institute's programs into the private sector for further development and commercialization, and NCI operates under a national policy to use the patent system to transfer Federally supported research to the private domestic sector. Reliance on patent law may limit the Institute's ability to recognize the rights of source countries and their indigenous people and provide compensation for their contributions. However, other legal instruments, such as contracts, can serve as interim measures to provide compensation to source countries and indigenous populations. The National Cancer Institute's Letter of Collection agreement (LOC, formerly the "Letter of Intent'), is an example of an alternative means that "fills-in the gaps' created by patent law and through which source countries may share in the benefits of natural product development.

摘要

美国国立癌症研究所(NCI)是美国政府负责癌症预防、诊断和治疗研究的主要机构。该研究所使命的一个关键组成部分是识别和开发治疗癌症及艾滋病的新的、有前景的疗法。多年来,这些努力包括一项调查天然产物以寻找潜在新治疗药物的计划。1986年,随着新筛选技术的出现,美国国立癌症研究所加大了对天然产物的探索力度,并开始在热带和亚热带地区进行全球范围的植物采集。认识到《生物多样性条约》的原则,NCI意识到持续获取这些国家的天然产物取决于该研究所认可这些来源国及其原住民的贡献的能力,并为他们提供足够的激励措施,以便为药物研发目的保护其自然资源。实现这一目标给美国国立癌症研究所带来了几个法律问题。作为美国政府的一个机构,NCI有一项辅助性法定使命,即促进将通过该研究所项目开发的技术转让给私营部门进行进一步开发和商业化,并且NCI依据一项国家政策运作,即利用专利制度将联邦支持的研究成果转让给国内私营部门。依赖专利法可能会限制该研究所认可来源国及其原住民权利并为其贡献提供补偿的能力。然而,其他法律手段,如合同,可以作为向来源国和原住民提供补偿的临时措施。美国国立癌症研究所的采集许可协议(LOC,以前称为“意向书”)就是一种替代手段的例子,它“填补了”专利法造成的“空白”,来源国可以通过它分享天然产物开发的益处。

相似文献

1
Legal issues in sharing the benefits of biodiversity prospecting.生物多样性勘探利益分享中的法律问题。
J Ethnopharmacol. 1996 Apr;51(1-3):93-102; discussion 102-9. doi: 10.1016/0378-8741(95)01352-0.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验